摘要
在西方人群中,凝血因子V莱顿(FVL)的携带关联是目前最常见的血栓形成倾向。FVL是由凝血因子V (FV)基因编码中的单基因点突变引起,FV会导致终身的促凝血因子状态,增加静脉血栓栓塞(VTE)的风险,也许会致命。它认为,21000年前人类发生突变,今天,西方人群中有3%-15%是携带者。一种潜在的危险突变如FVL,如果不刨根问底的话,应当是罕见的;在人类的进化过程中,这种突变应该是选择性地减少。因此,为了繁衍,FVL一定赋予了携带者一种进化优势。低风险的大量出血和增加的繁殖力也许给了携带者一种优势。本文中我们对简单背景进行了更新,并且讨论了可能的进化利弊。
关键词: 莱顿第五因子,进展,优势,产科并发症,出血,APC阻力
Current Medicinal Chemistry
Title:On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL)
Volume: 22 Issue: 32
Author(s): P.G. Lindqvist
Affiliation:
关键词: 莱顿第五因子,进展,优势,产科并发症,出血,APC阻力
摘要: Carriership of coagulation factor V Leiden (FVL) is by far the most common thrombophilia in Western populations. FVL is caused by a single point mutation in the gene coding for coagulation factor V (FV) causing a lifelong procoagulatory state with an increased risk of venous thromboembolism (VTE) which might be fatal. It is believed that the mutation occurred in one person 21,000 years ago and today 3% to 15% of the Western populations are carriers. A potentially dangerous mutation such as FVL ought to be rare and should have been reduced, if not eradicated, by selection during the course of human evolution. Thus, FVL must confer the carriers with an evolutionary advantage in order to be so prevalent. Lower risk of profuse bleeding and increased fecundity might give carriers an advantage. In this paper we give an updated short background and discuss possible evolutionary advantages and disadvantages.
Export Options
About this article
Cite this article as:
P.G. Lindqvist , On the Evolutionary Advantage of Coagulation Factor V Leiden (FVL), Current Medicinal Chemistry 2015; 22 (32) . https://dx.doi.org/10.2174/0929867322666151001121707
DOI https://dx.doi.org/10.2174/0929867322666151001121707 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Fondaparinux
Current Pharmaceutical Design Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews A Rare Case Report of Dabigatran Induced Oral Ulcers
Current Drug Safety Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Clinical Characteristics of Inpatients with Coronavirus Disease 2019 and Acute Ischemic Stroke: From Epidemiology to Outcomes
Current Neurovascular Research Pharmacology and Clinical Effect of Platonin, a Cyanine Photosensitizing Dye: Potential Molecular Targets
Current Pharmaceutical Biotechnology Microfluidic System Based on Thermoexpandable Polymer for on Chip Blood Coagulation Testing
Micro and Nanosystems Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Fibrin Clot Properties and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS
Current Drug Metabolism Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews